Figures & data
Figure 1. Patient disposition. At baseline, 101 patients were enrolled in the study, 90 of whom completed the required two visits to the study site. Per protocol, patients were assessed at baseline and were to return to study sites between weeks 0 and 16 for an interval visit at the first clinically significant change in disease status (e.g. disease improvement or flare) or treatment. If no interval visit was made, a week-16 final assessment was required. Because only 10 patients had an interval visit, the majority of whom represented one clinical site and had no subsequent follow-up visit, these data were combined and analyzed with 16-week follow-up data.
Table 1. Patient demographics and baseline characteristics.
Table 2. Frequency of report of symptoms.
Figure 2. Symptoms bother rankings. “Other” includes all symptoms defined as “Other” in and as well as any additional symptoms ranked as first, second or third most bothersome by <5% of patients for each ranking, including symptoms coded as dry skin, flaking/scaling (scalp area), nail problems, skin thickness, tired/fatigue, skin irritation, joint inflammation/swelling, joint stiffness and skin inflammation/swelling, skin sensitivity/tenderness and flare-ups.
Table 3. Symptom reporting and bother rankings.
Figure 3. Frequency of reporting by impact areas for psoriasis-only and psoriasis + psoriatic arthritis patients. Impact areas are described in . A patient was counted in an impact area if the patient made at least one statement that was coded in that category. p Values are provided for any statistically significant differences between psoriasis and psoriasis + psoriatic arthritis patients.
